Professional Documents
Culture Documents
Market cap…………… $15 million • Adamis Completes $10 million Stock Purchase [Funding] Agreement 11/11/10
Fiscal year end……... March 31st
• Adamis Completes Acquisition of Prostate Drug Candidates 10/19/10
Executive Mgmt.
has two (2) wholly-owned subsidiaries:
Dennis J. Carlo, Ph.D.
President and CEO Adamis Laboratories, Inc. (specialty pharmaceuticals), which has
a line of prescription products in the anti-inflammatory, allergy and
Robert O. Hopkins, CFO respiratory field. Adamis Labs’ has just begun pre-launch activities for additional products.
David J. Marguglio, Senior VP Adamis Therapeutics, Inc. (biotechnology), which is primarily focused on the development
of patented, proprietary technologies for the potential treatment of human prostate cancer.
Thomas Moll, Ph.D.
Vice President /Research ♦ ♦ BLOCKBUSTER POTENTIAL ♦ ♦
Adamis Therapeutics is developing first-in-class products with “blockbuster” potential.
Karen K. Daniels
During the 4th quarter of 2010, the Company obtained exclusive worldwide rights to
Vice President /Operations
three new compounds for the treatment of prostate cancer (see 10/19/10 news below).
Richard L. Aloi SAN DIEGO -- Oct. 19, 2010 -- Adamis Pharmaceuticals Corporation (OTCBB: ADMP),
Adamis Laboratories, President announced the acquisition from Colby Pharmaceuticals of the remaining exclusive license
agreements relating to the remaining 2 of 3 drug product candidates for the treatment of
prostate cancer (PCa). Adamis has now acquired the exclusive licenses covering
three (3) molecule compounds, named APC-100, APC-200 and APC 300.
Over $18 million in U.S. Gov’t funds have been awarded for the development of APC-100,
APC-200 and APC-300 by: the Congressionally Directed Medical Research Program, the
GREATER SAN DIEGO
Prostate Cancer Research Program (PCRP), and the National Cancer Institute (NCI).
Headquarters
APC-100 has also been privately funded by Michael Milken's Prostate Cancer Foundation.
Adamis Pharmaceuticals Corp.
2658 Del Mar Heights Road
Del Mar, California 92014 In 2006 and 2007, both the APC-100 and APC-200 compounds won the prestigious
National Cancer Institute Rapid Award, which is given to drugs the NCI considers to be
Tel. # 858.401.3984 the most promising new drugs for the treatment of cancer.
info@adamispharma.com
Adamis Pharmaceuticals Corporation has strong patent claims in the United States
and in certain foreign markets with other foreign applications in progress.
www.AdamisPharma.com
DISCOVER WHY ADAMIS IS DEVELOPING A CANCER VACCINE
TeloB-VAX utilizes the patient’s own B cells as antigen producing and antigen presenting cells. (B cells represent approx. 12% of
circulating blood cells).
Adamis believes its technology offers major advantages over the FDA approved Provenge® vaccine. These advantages, include:
1) prolonged antigen presentation by B cells (5 days) as compared to the short presentation time by dendritic cells (12 hours),
2) a unique patented platform technology using a universal cancer antigen that is increased in approximately 85% of all tumors,
3) immunity after a single injection, 4) no need for complicated culture procedures, 5) significantly fewer steps, 6) lower cost and
7) technology built on strong stringent scientific rationale. NOTE: TeloB-VAX may very well be called a “universal cancer vaccine”
that could induce immunity against multiple cancer types as well as targeting the specific cancer stem cell.
Currently Adamis is planning a Phase 2 study in castrate resistant prostate cancer (CRPC) patients. The study will be conducted at the
University of Wisconsin Carbone Cancer Center and at UCSD. Adamis is expected to submit an IND application to the FDA within weeks.
Please see www.AdamisPharma.com for in-depth medical product descriptions, key attributes and market potential data.
The natural brevity of this fact sheet has excluded other significant corporate assets, including wholly-owned subsidiary, Adamis
Laboratories’ intellectual property rights for a microbicide contraception gel product candidate named Savvy® (C31G).
Copyright © 2011 Heritage First Capital / www.heritagefirst.com / Tel. 407.444.5959 / Greater Orlando